Pharming Group N.V. (PHAR)

Pharming Group Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	376.13	297.2	245.32	205.62	198.87
Revenue Growth (YoY)	26.56%	21.15%	19.30%	3.40%	-6.27%
Cost of Revenue	45.5	35.4	25.21	17.56	21.14
Gross Profit	330.63	261.8	220.1	188.06	177.73
Selling, General & Admin	210.95	189.45	179.93	131.82	96.42
Research & Development	100.37	83.15	68.91	52.53	70.37
Other Operating Expenses	317.85	274.78	272.19	198.87	169.41
Total Operating Expenses	629.17	547.38	521.03	383.22	336.2
Operating Income	-298.53	-285.57	-300.93	-195.16	-158.47
Total Non-Operating Income (Expense)	-13	0.13	-6.63	-3.25	9.52
Pretax Income	12.85	-8.49	-12.01	14.99	23.08
Provision for Income Taxes	10.31	3.35	-1.46	1.31	7.08
Net Income	2.85	-11.84	-10.55	13.67	16
Minority Interest in Earnings	0.31	-	-	-	-
Net Income to Common	2.85	-11.84	-10.55	13.67	16
Net Income Growth	-	-	-	-14.52%	-57.62%
Shares Outstanding (Basic)	71	67	66	65	64
Shares Outstanding (Diluted)	71	79	73	71	70
Shares Change (YoY)	-9.25%	8.26%	2.59%	0.85%	2.70%
EPS (Basic)	0.04	-0.18	-0.16	0.21	0.25
EPS (Diluted)	0.04	-0.18	-0.16	0.19	0.23
EPS Growth	-	-	-	-17.39%	-58.18%
Free Cash Flow	53.96	-2.59	-18.74	21.08	27.1
Free Cash Flow Growth	-	-	-	-22.21%	-65.68%
Free Cash Flow Per Share	-	-0.03	-0.26	0.30	0.39
Gross Margin	87.90%	88.09%	89.72%	91.46%	89.37%
Operating Margin	-79.37%	-96.09%	-122.67%	-94.91%	-79.68%
Profit Margin	0.67%	-3.98%	-4.30%	6.65%	8.04%
FCF Margin	14.35%	-0.87%	-7.64%	10.25%	13.63%
EBITDA	-287.32	-269.5	-285	-181.98	-138.86
EBITDA Margin	-76.39%	-90.68%	-116.18%	-88.50%	-69.82%
EBIT	-298.53	-285.57	-300.93	-195.16	-158.47
EBIT Margin	-79.37%	-96.09%	-122.67%	-94.91%	-79.68%
Effective Tax Rate	80.25%	-39.44%	12.19%	8.76%	30.69%

Updated Mar 12, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q